MENU
+Compare
HELX
ETF ticker: BATS
AS OF
Aug 7, 11:36 AM (EDT)
Price
$27.56
Change
-$0.04 (-0.14%)
Net Assets
13.79M

HELX stock forecast, quote, news & analysis

The investment seeks capital appreciation... Show more

Category: #Health
HELX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the ETF lost 0.00% with an average daily volume of 0 shares traded.The ETF tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for HELX with price predictions
Aug 06, 2025

HELX in -1.81% downward trend, falling for three consecutive days on August 06, 2025

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where HELX declined for three days, in of 301 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for HELX moved out of overbought territory on July 11, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on August 06, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on HELX as a result. In of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for HELX turned negative on July 31, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .

HELX broke above its upper Bollinger Band on July 09, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HELX advanced for three days, in of 330 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 231 cases where HELX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), AstraZeneca PLC (NASDAQ:AZN), Bristol-Myers Squibb Co (NYSE:BMY), Regeneron Pharmaceuticals (NASDAQ:REGN), IQVIA Holdings (NYSE:IQV), Exact Sciences Corp (NASDAQ:EXAS), Guardant Health (NASDAQ:GH), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sarepta Therapeutics (NASDAQ:SRPT).

Industry description

The investment seeks capital appreciation. Under normal market conditions, the fund invests at least 80% of its net assets in equity securities of companies that are relevant to its investment theme of genomic advancements. The fund invests predominantly in common stock. Although it may invest across economic sectors, the fund concentrates its investments in health care related industries. It is non-diversified.

Market Cap

The average market capitalization across the Franklin Genomic Advancements ETF ETF is 34.68B. The market cap for tickers in the group ranges from 178.33M to 739.66B. LLY holds the highest valuation in this group at 739.66B. The lowest valued company is VYGR at 178.33M.

High and low price notable news

The average weekly price growth across all stocks in the Franklin Genomic Advancements ETF ETF was 29%. For the same ETF, the average monthly price growth was 63%, and the average quarterly price growth was 78%. FDMT experienced the highest price growth at 30%, while TWST experienced the biggest fall at -25%.

Volume

The average weekly volume growth across all stocks in the Franklin Genomic Advancements ETF ETF was 2%. For the same stocks of the ETF, the average monthly volume growth was 18% and the average quarterly volume growth was 13%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 60
P/E Growth Rating: 73
Price Growth Rating: 56
SMR Rating: 80
Profit Risk Rating: 81
Seasonality Score: -26 (-100 ... +100)
View a ticker or compare two or three
HELX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
Franklin Templeton ETF TrustONE FRANKLIN PARKWAYSAN MATEO
Phone
N/A
Web
etf.franklintempleton.com